secwatch.observer — SEC 8-K summary
======================================

Issuer:     NeuroPace Inc (NPCE)
CIK:        0001528287
Form:       8-K
Filed at:   2023-03-02T23:59:59+00:00
Accession:  0001528287-23-000005
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeuroPace Q4 revenue $12.8M (+16% YoY); guides FY2023 revenue $50-52M
---------------------------------------------------------------------

- Q4 2022 revenue $12.8M (+16% YoY); initial implant revenue $9.8M (+15% YoY).
- Full year 2022 revenue $45.5M (+1% YoY); net loss $47.1M vs $36.1M in 2021.
- FY2023 guidance: revenue $50-52M (10-14% growth), gross margin 69-71%, op expenses $75-77M.
- DIXI Medical distribution contributed $1.6M in Q4; NAUTILUS study for primary generalized epilepsy ongoing.
- Cash burn reduced to ~$15M in H2 2022 from ~$23M in H1; cash $77.4M at year-end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1528287/000152828723000005/0001528287-23-000005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1528287/000152828723000005/npce-20230302.htm
  HTML page:      https://secwatch.observer/filing/0001528287-23-000005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer